A Review on Novel Progressions in Intravenous (IV) agents for Anesthesia

Abstract

One of the main medical proficiencies involved with the procedure of patient’s perioperative care before, during and after operation is anesthesiology. This field of science has made a lot of hopeful progression in detection of new, secure, impressive, and productive procedures for proper management of patients. The most effective sedative–hypnotic agents which categorized in titratable intravenous medication, have highest medicinal effect and the least side effects. Currently a high effort is employed for developing such drugs with central focus on improving the available drugs structures for modifying their pharmacokinetic (PK) and pharmacodynamic (PD) characteristics. Various drugs are investigating for achieving more progression which includes etomidate, midazolam analogues, and diprivan. One of the main approaches for investigating about the development of anesthesia agents is swift screening of related libraries of molecular structure which evaluate phenotypic or structural assays of anesthetic and receptor interactions of agents. Due to the recently high demands of clinical operations for more sufficient anesthesia agents, the progression of anesthetic agents is experiencing a new generation of advanced clinical trials. In this regard, the current study is trying to provide a brief look on the newest anesthetic drugs and novel developed procedures which simplify this objective. This comprehensive study reviews would clarify the novel technology of progression of drugs which do not have physical addiction effects, distinctive system of anesthetic drug delivery, and the novel failures of drugs and their facilities.